A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) S-0820
Sponsor: Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants with Advanced Solid Tumors
Sponsor: Arcus Biosciences, Inc.
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer (NRG-GY009)
Sponsor: NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Sponsor: NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Sponsor: National Cancer Institute
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Sponsor: ECOG-ACRIN Cancer Research Group
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

No Active Trials

A Phase III Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection (Rebiotix Open-Label)
Sponsor: Rebiotix Inc.
Principal Investigator: David Yoho, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerablility of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Regimen in Virologically-suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain with an INI + TAF/FTC ARV Regimen
Sponsor: Janssen Scientific Affairs, LLC
Principal Investigator: Michael Horberg, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

An open-label, non-randomized, prospective observational cohort study to assess post-procedural outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (EssureĀ®) or laparoscopic tubal sterilization (POET-ESSURE)
Sponsor: Bayer HealthCare, LLC
Principal Investigator: Kevin Smith, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768